Literature DB >> 23372314

Liver Transplantation for HCC: A Review.

Rahul Kakodkar1, A S Soin.   

Abstract

Hepatocellular carcinoma (HCC) often occurs in patients with chronic liver disease or cirrhosis. Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver. Limitations in organ availability, necessitate stringent selection of patients who would likely to derive most benefit. Selection criteria have considered tumor size, number, volume as well as biological features. The Milan criteria set the benchmark for tumors that would benefit from liver transplantation but were found to be excessively restrictive. Modest expansion in criteria has also been shown to be associated with equivalent survival. Microvascular invasion is the single most important adverse prognostic factor for survival. Living donor liver transplantation has expanded donor options and has the advantage of lower waiting period and not impacting the non-HCC waiting list. Acceptable outcomes have been obtained with living donor liver transplantation for larger and more numerous tumors in the absence of microvascular invasion. Downstaging of tumors to prevent progression while waiting for an organ or for reduction in size to allow enrolment for transplantation has met with variable success.

Entities:  

Keywords:  Alpha-fetoprotein; Chemoembolization; Hepatocellular carcinoma; Liver transplantation; Living donor; Microvascular invasion; Milan criteria; Radiofrequency ablation

Year:  2011        PMID: 23372314      PMCID: PMC3259181          DOI: 10.1007/s12262-011-0387-2

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  135 in total

1.  Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation.

Authors:  A Vitale; M L Volk; M Gambato; G Zanus; F D'Amico; A Carraro; A Pauletto; P Bonsignore; M Scopelliti; M Polacco; F Russo; M Senzolo; P Burra; A Romano; P Angeli; U Cillo
Journal:  Transplant Proc       Date:  2010-05       Impact factor: 1.066

2.  Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database.

Authors:  Richard B Freeman; Abigail Mithoefer; Robin Ruthazer; Khanh Nguyen; Anthony Schore; Ann Harper; Erick Edwards
Journal:  Liver Transpl       Date:  2006-10       Impact factor: 5.799

3.  Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma.

Authors:  D von Schweinitz; A Faundez; B Teichmann; T Birnbaum; A Koch; H Hecker; S Glüer; J Fuchs; T Pietsch
Journal:  Int J Cancer       Date:  2000-01-15       Impact factor: 7.396

4.  Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.

Authors:  J M Llovet; J Fuster; J Bruix
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

Authors:  Christian Toso; Shaheed Merani; David L Bigam; A M James Shapiro; Norman M Kneteman
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

6.  Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Srinath Chinnakotla; Gary L Davis; Sugam Vasani; Peter Kim; Koji Tomiyama; Edmund Sanchez; Nicholas Onaca; Robert Goldstein; Marlon Levy; Göran B Klintmalm
Journal:  Liver Transpl       Date:  2009-12       Impact factor: 5.799

7.  MicroRNA expression, survival, and response to interferon in liver cancer.

Authors:  Junfang Ji; Jiong Shi; Anuradha Budhu; Zhipeng Yu; Marshonna Forgues; Stephanie Roessler; Stefan Ambs; Yidong Chen; Paul S Meltzer; Carlo M Croce; Lun-Xiu Qin; Kwan Man; Chung-Mau Lo; Joyce Lee; Irene O L Ng; Jia Fan; Zhao-You Tang; Hui-Chuan Sun; Xin Wei Wang
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.

Authors:  Shuji Sumie; Ryoko Kuromatsu; Koji Okuda; Eiji Ando; Akio Takata; Nobuyoshi Fukushima; Yasutomo Watanabe; Masamichi Kojiro; Michio Sata
Journal:  Ann Surg Oncol       Date:  2008-03-07       Impact factor: 5.344

10.  Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.

Authors:  Chi-lai Ho; Sirong Chen; David W C Yeung; Thomas K C Cheng
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more
  10 in total

1.  Inappropriate inferences from registry data: Pitfalls of inaccurate data handling?

Authors:  Rahul Kakodkar
Journal:  Indian J Gastroenterol       Date:  2017-03-30

Review 2.  Liver Transplantation in India: At the Crossroads.

Authors:  Sanjay Nagral; Aditya Nanavati; Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2015-11-12

Review 3.  The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Vivek A Saraswat; Anil Arora; Ajay Duseja; Mahesh K Goenka; Deepali Jain; Premashish Kar; Manoj Kumar; Vinay Kumaran; Kunisshery M Mohandas; Dipanjan Panda; Shashi B Paul; Jeyamani Ramachandran; Hariharan Ramesh; Padaki N Rao; Samir R Shah; Hanish Sharma; Ragesh B Thandassery
Journal:  J Clin Exp Hepatol       Date:  2014-05-22

Review 4.  Treatment algorithms for managing hepatocellular carcinoma.

Authors:  Vivek A Saraswat; Gaurav Pandey; Sachin Shetty
Journal:  J Clin Exp Hepatol       Date:  2014-06-06

Review 5.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

6.  Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria.

Authors:  Yusuf Gunay; Necdet Guler; Onur Yaprak; Murat Dayangac; Murat Akyildiz; Gulum Altaca; Yildiray Yuzer; Yaman Tokat
Journal:  Indian J Surg       Date:  2014-04-24       Impact factor: 0.656

7.  Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition.

Authors:  Xiao-lin Zhu; Yan-li Wang; Jie-peng Chen; Li-li Duan; Pei-fang Cong; Ying-chun Qu; Jesse Li-Ling; Mei-xia Zhang
Journal:  Tumour Biol       Date:  2014-02

8.  Impact of endoscopic ultrasound-guided fine-needle aspiration in prospective liver transplant recipients with hepatocellular carcinoma and lymphadenopathy.

Authors:  Narendra S Choudhary; Rajesh Puri; Sanjiv Saigal; Prashant Bhangui; Neeraj Saraf; Vinit Shah; Mukesh Nasa; Haimanti Sarin; Mridula Guleria; Randhir Sud; Arvinder S Soin
Journal:  Indian J Gastroenterol       Date:  2016-12-08

9.  Risk Factors for Hepatocellular Carcinoma Recurrence and Survival after Liver Transplantation in Patients with HCV-Related Cirrhosis.

Authors:  Raphael Iglesias de Oliveira Vidal; Edison Iglesias de Oliveira Vidal; Basilio de Bragança Pereira; Cachimo Combo Assane; Alexandre Ribeiro; Emilia Matos do Nascimento; Fernando Gomes Romeiro; Joaquim Ribeiro Filho
Journal:  Biomed Res Int       Date:  2020-10-17       Impact factor: 3.411

Review 10.  Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome.

Authors:  A Kornberg
Journal:  ISRN Hepatol       Date:  2014-03-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.